Clinical Trials on Fibrocystic Breast Disease

Total 378295 results

M.D. Anderson Cancer Center

Terminated

Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer

Breast Neoplasm | Inflammatory Breast Carcinoma

United States
M.D. Anderson Cancer Center
Novartis

Completed

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Breast Cancer

United States
M.D. Anderson Cancer Center
Boehringer Ingelheim

Terminated

Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)

Breast Cancer

United States
GlaxoSmithKline

Completed

Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer

Neoplasms, Breast

United States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Breast Cancer

United States
European Organisation for Research and Treatment...
Swiss Group for Clinical Cancer Research; Swedish Breast Cancer Group; Anglo...

Completed

Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Breast Cancer

France, Switzerland, Poland, Sweden, Belgium, Netherlands, United Kingdom, Portugal, Slovenia
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Neoplasms, Breast

United States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
Washington University School of Medicine
Biovica

Not yet recruiting

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

Metastatic Breast Cancer | Unresectable Breast Cancer

United States
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Ahon Pharmaceutical Co., Ltd.

Recruiting

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Female Breast Cancer

China
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer

China
The Institute of Molecular and Translational Medicine...
University Hospital Olomouc

Recruiting

Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer (DISC)

Metastatic Breast Cancer | Breast Neoplasm Female

Czechia
Stanford University
National Institutes of Health (NIH)

Recruiting

Magnetic Resonance Imaging of Breast Cancer

Breast Cancer | Breast Cancer Non-invasive Breast Cancer

United States
Washington University School of Medicine
United States Department of Defense; Rising Tide Foundation

Active, not recruiting

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

Breast Cancer | Breast Carcinoma | Malignant Neoplasm of Breast

United States
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Advanced Breast Cancer | Metastatic Breast Cancer

China
University of Alabama at Birmingham
Genentech, Inc.; Breast Cancer Research Foundation

Completed

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

Breast Cancer | Breast Neoplasm | Cancer of the Breast

United States
The Netherlands Cancer Institute
Institut Curie

Terminated

Pre- Versus Postoperative Accelerated Partial Breast Irradiation (PAPBI-2)

Breast Cancer | Neoplasms, Breast | Cancer of the Breast

France, Netherlands, Portugal, Spain
Onco Medical Consult GmbH
Eli Lilly and Company; Institut fuer Frauengesundheit

Unknown

Implementing Patients´ Competence in Oral Breast Cancer Therapy (IMPACT)

Advanced Breast Cancer | Metastatic Breast Cancer
AstraZeneca

Completed

A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg (FINDER II)

Advanced Breast Cancer | Metastatic Breast Cancer

Belgium, Turkey, Canada, Poland, Romania, Hungary, France, Czechia
University of California, Irvine

Completed

Overall Diet Quality and Breast Cancer Risk

Invasive Breast Cancer | Incident Breast Cancer
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Universitair Ziekenhuis Brussel

Unknown

Opting for Breast Reconstruction After Mastectomy or Not: Search for Influencing Factors

Breast Reconstruction | Mastectomy | Breast Cancer Female
Neovii Biotech

Terminated

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment

Advanced Breast Cancer | Metastatic Breast Cancer

Spain, Austria, France, Germany, Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors

Cancer Survivor | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Postmenopausal

United States
University Hospital, Grenoble

Recruiting

Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone (Néo-APBI-01)

Radiation Therapy, Breast Cancer, Sequential Partial Breast Irradiation | Intermediate and High-risk Luminal and Triple Negative Breast Cancer

France
Medical College of Wisconsin

Active, not recruiting

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Breast Cancer | Breast Neoplasms | Breast Cancer Stage IV | Breast Adenocarcinoma | Breast Cancer Stage | Breast Cancer Invasive | Breast Cancer in Situ

United States
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group; Canadian Cancer Trials Group; Southwest Oncology... and other collaborators

Completed

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

HER2 Positive Breast Carcinoma | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Peru, South Africa
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Active, not recruiting

Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness) (PTW)

Stage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation
Abramson Cancer Center at Penn Medicine

Active, not recruiting

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Advanced Breast Cancer | Metastatic Breast Cancer | BRCA1 Mutation | BRCA2 Mutation | Locally Advanced Breast Cancer

United States
GlaxoSmithKline

Active, not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

Neoplasms, Breast

United States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
Stanford University
National Cancer Institute (NCI)

Completed

Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer

Stage 0 Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors

Stage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer

United States
Fred Hutchinson Cancer Center
GlaxoSmithKline

Completed

Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer

Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer... and other conditions

Uganda
Jules Bordet Institute

Recruiting

PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. (PRISMA)

TNBC - Triple-Negative Breast Cancer

Belgium
University Hospital Tuebingen
University Hospital Freiburg; University Hospital Ulm

Recruiting

Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer

TNBC - Triple-Negative Breast Cancer

Germany
Huihua Xiong

Not yet recruiting

Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer

Metastatic Triple-negative Breast Cancer

China
Aiping Shi

Recruiting

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC)

China
Fujian Cancer Hospital

Not yet recruiting

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
PharmAbcine
Merck Sharp & Dohme LLC

Recruiting

Olinvacimab With Pembrolizumab in Patients With mTNBC

Metastatic Triple-Negative Breast Cancer

Australia
Gilead Sciences
Parexel; IQVIA RDS (Shanghai) Co., Ltd.; Medidata Solutions; Q Squared Solutions...

Active, not recruiting

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

Metastatic Triple-negative Breast Cancer

China
Daiichi Sankyo

Completed

Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer

HER2-negative Breast Cancer | HER2-low Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
Yale University
Iovance Biotherapeutics, Inc.

Completed

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
University of Alabama at Birmingham
GlaxoSmithKline; AbbVie; Breast Cancer Research Foundation of Alabama

Active, not recruiting

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Case Comprehensive Cancer Center

Completed

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Miguel Martín Jiménez
UNC Lineberger Comprehensive Cancer Center; Hospital Universitario Ramon y... and other collaborators

Active, not recruiting

Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast Cancer

Breast Cancer | Breast Cancer Stage II-III

Spain

Clinical Trials on Fibrocystic Breast Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations